NARA Discovery
Article Details
← Back to Search Results
Journal Article

Antimicrobial activity of dalbavancin against Gram-positive bacteria isolated from patients hospitalized with bloodstream infection in United States and European medical centers (2018–2020)

Helio S. Sader; Mariana Castanheira; Michael D. Huband; Dee Shortridge; Cecilia G. Carvalhaes; Rodrigo M. Mendes
European Journal of Clinical Microbiology & Infectious Diseases · Vol. 41, Issue 5 · pp. 867-873 · 2022

Abstract

Dalbavancin and comparators were susceptibility tested against 8643 Gram-positive bacteria from 74 hospitals located in Europe and the United States by broth microdilution method. The most common organisms were Staphylococcus aureus (45.2%), Enterococcus faecalis (12.2%), and Staphylococcus epidermidis (8.9%), but rank order varied markedly by geographic region. Dalbavancin demonstrated potent activity and broad spectrum, with MIC 90 values of 0.03 mg/L for Staphylococcus aureus , β-haemolytic streptococci, and viridans group streptococci; 0.06 mg/L for Enterococcus faecalis and Staphylococcus epidermidis ; and 0.12 mg/L for vancomycin-susceptible Enterococcus faecium . All organisms, except vancomycin-resistant enterococci and 1 Staphylococcus haemolyticus isolate, were inhibited at ≤ 0.25 mg/L of dalbavancin.

Bibliographic Information

JournalEuropean Journal of Clinical Microbiology & Infectious Diseases
PublisherSpringer
Publication Date2022-05-01
Publication Year2022
Volume41
Issue5
Pages867-873
Document TypeJournal Article
Print ISSN0934-9723
eISSN1435-4373
DOI10.1007/s10096-022-04437-0

Access Information

NARA Access Coverage1982-01-01~Current
Journal Homepagehttps://www.springer.com/journal/10096
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.